Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'

Stock Markets Oct 15, 2021 04:51AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: Traders work on the main trading floor of the New York Stock Exchange shortly after the opening bell of the trading session in the Manhattan borough of New York City, January 7, 2016. REUTERS/Brendan McDermid/File Photo/File Photo

By Lewis Krauskopf

NEW YORK (Reuters) - Sluggish U.S. biotech shares could require a wave of deal-making or exciting clinical trial results if the sector wants to join the stock market's party after lagging Wall Street's broad advance this year.

More certainty about the direction of prescription drug regulation, including the prospects for tougher pricing legislation, also could bolster the stocks.

An index of S&P 500 biotech companies is up 2% so far in 2021, while the overall S&P 500 has gained more than 18%. A closely watched ETF that better measures small and mid-cap biotech companies -- the SPDR S&P Biotech (NYSE:XBI) ETF -- is down nearly 10% for the year, and 27% from its high reached in February.

About $2.5 billion has flowed out of healthcare ETFs on a net basis since Aug. 31, or about 3% of total assets of those funds, according to Jefferies (NYSE:JEF) strategist Steven DeSanctis. In the week ending Oct. 6, the SPDR biotech ETF saw its biggest weekly outflow on record, according to Refinitiv Lipper data.

After a strong 2020 particularly for smaller biotech stocks, investors said the group was due to back off. But biotech shares have been lost in broad investment themes this year, market watchers said.

They cited a tug-of-war between stocks expected to shine in an improving economy, such as energy and banks, and big tech and growth shares that strengthened during economic unease.

“It seems like healthcare, and biotech specifically, is sort of in no man’s land on a year-to-date basis,” DeSanctis said. “The swings in the market have either been, I want to own cyclicals and or I want to be defensive.”

Among large biotech stocks, Amgen (NASDAQ:AMGN), a member of the Dow Jones Industrial Average, is down 10% so far in 2021, while Vertex Pharmaceuticals (NASDAQ:VRTX) has slumped 23%.

The S&P 500 biotech index trades at price-to-earnings ratio of 10.2 times forward earnings estimates, a 50% discount to the S&P 500's P/E ratio of 20.4, according to Refinitiv Datastream data.

“When you look at the large caps, the growth opportunities and the prospects there are a lot more in question than they have been historically,” said Marshall Gordon, senior healthcare analyst at Clearbridge Investments.

For smaller companies, investors often look for a pickup in acquisitions to help improve biotech valuations. Healthcare companies are sitting on almost $500 billion in cash, a record amount, according to Jefferies analysts.

"If we start to see more M&A, that should help trigger more positive sentiment around the space,” said Sahak Manuelian, head of equity trading at Wedbush Securities.

Not all biotech stocks have struggled this year. Shares of COVID-19 vaccine makers, Moderna (NASDAQ:MRNA) and BioNTech, have surged more than 200% so far in 2021.

But recent industry setbacks could be souring sentiment: Biogen (NASDAQ:BIIB)'s new and controversial Alzheimer's treatment has had an uncertain launch, Apellis Pharma shares tumbled following disappointing data for its experimental eye drug, and U.S. regulators placed a hold on studies of Allogene Therapeutics (NASDAQ:ALLO)' cancer medicine.

Data in coming months from major medical conferences, including a hematology meeting in December, could reinvigorate interest in biotech, Manuelian said.

Regulatory obstacles also persist. SVB Leerink analyst Geoffrey Porges said in a note this week that it was "difficult to see" a broad rally in the biopharma group in part because of "the enduring overhang of drug pricing regulation risks, which in our view is likely to last until the end of the year."

Uncertainty about the Food and Drug Administration, the industry's main regulator for which President Biden has yet to nominate a permanent commissioner, may also be clouding the investing environment, investors said.

"There have been a number of regulatory decisions that have been surprising," Gordon said. "There are concerns that FDA is either getting harder or is just less predictable."

Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'

Related Articles

Israel stocks lower at close of trade; TA 35 down 0.19%
Israel stocks lower at close of trade; TA 35 down 0.19% By - Jul 06, 2022 – Israel stocks were lower after the close on Wednesday, as losses in the Oil & Gas, Real Estate and Banking sectors led shares lower. At the close in Tel Aviv, the...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email